Egypt Biosimilars Market (2024-2030) Outlook | Trends, Companies, Share, Industry, Revenue, Analysis, Forecast, Size, Value & Growth

Market Forecast By Product (Insulin, Follitropin, Calcitonin, Glucagon, Teriparatide, Others), By Indication (Oncology, Offsite Treatment, Chronic Disorders, Blood Disorders, Infectious Diseases, Others), By Manufacturing (Outsourced, In-house) And Competitive Landscape

Product Code: ETC069971 Publication Date: Jun 2021 Updated Date: Feb 2024 Product Type: Report
Publisher: 6Wresearch No. of Pages: 70 No. of Figures: 35 No. of Tables: 5

Topics Covered in the Egypt Biosimilars Market Report

Egypt Biosimilars Market report thoroughly covers the market by product, by indication, and by manufacturing. The market outlook report provides an unbiased and detailed analysis of the ongoing market trends, opportunities/high growth areas, and market drivers which would help the stakeholders to devise and align their market strategies according to the current and future market dynamics.

Egypt Biosimilars Market Synopsis

The Egypt biosimilars market is gaining traction as it offers a cost-effective alternative to expensive biologic drugs. As the country grapples with rising healthcare costs and an increasing burden of chronic diseases, biosimilars are being touted as a solution to improve accessibility to essential medications. The market is driven by a growing demand for affordable healthcare solutions, supportive government policies, and the patent expiration of several blockbuster biologic drugs, which has opened the door for biosimilar manufacturers.

According to 6Wresearch, the Egypt Biosimilars Market size is expected to grow at a CAGR of 6.3% during the forecast period 2024-2030. The primary drivers of biosimilar adoption in Egypt include economic factors such as the high cost of patented biologics, leading to a push for more affordable biosimilar alternatives. Increased prevalence of chronic diseases such as diabetes and cancer also necessitates a more cost-effective drug provision. Government initiatives promote the biosimilar industry through policy reforms and direct investments, creating a favorable business environment and incentivizing local production. Also, increasing local biosimilar manufacturing capability is observable. This is likely to lessen the dependency on imported drugs and establish Egypt as a regional hub for pharmaceutical innovation. The alignment of biosimilars with national health goals is further encouraging public-private partnerships. These collaborations pave the way for improving manufacturing standards, and sharing of technological expertise. These are some factors estimated to boost the Egypt Biosimilars Market growth.

Government Initiatives Introduced in the Egypt Biosimilars Market

The Egyptian government has launched several initiatives aimed at bolstering the biosimilars market. The favorable regulatory reforms, which simplify the approval pathways for biosimilars, while still maintaining international safety standards. Financial incentives, such as tax breaks and funding for research and development, are also being provided to encourage local production and attract foreign investment. 

Key Players in the Egypt Biosimilars Market

The market is witnessing the emergence of significant players, both local and international. Companies like Minapharm Pharmaceuticals and Amoun Pharmaceutical Company have taken the lead in developing and marketing biosimilars within Egypt. These key players are investing in R&D and forming strategic alliances to enhance their market presence.

Future Insights of the Egypt Biosimilars Market

The Egypt biosimilars industry is poised for considerable growth. As regulatory frameworks become more streamlined and the market more educated about biosimilars, acceptance and usage are expected to rise. Continued government support and investment in healthcare infrastructure will likely further fuel market growth. 

Market Analysis by Product

According to Dhaval, Research Manager, 6Wresearch, insulin represents a particularly growing segment. Owing to the rising prevalence of diabetes across the nation, coupled with increasing push for affordable treatment options, biosimilar insulins are gaining considerable traction. 

Market Analysis by Indication

Based on the indication, oncology is dominating the Egypt Biosimilars Market share. The rising incidence of cancer in the population, along with the high cost associated with originator oncology treatments, steers the demand for more accessible and affordable biosimilar options. 

Key attractiveness of the report

  • 10 Years Market Numbers.
  • Historical Data Starting from 2020 to 2023.
  • Base Year: 2023.
  • Forecast Data until 2030.
  • Key Performance Indicators Impacting the Market.
  • Major Upcoming Developments and Projects.

Key Highlights of the Report:

  • Egypt Biosimilars Market Outlook
  • Market Size of Egypt Biosimilars Market, 2023
  • Forecast of Egypt Biosimilars Market, 2030
  • Historical Data and Forecast of Egypt Biosimilars Revenues & Volume for the Period 2020 - 2030
  • Egypt Biosimilars Market Trend Evolution
  • Egypt Biosimilars Market Drivers and Challenges
  • Egypt Biosimilars Price Trends
  • Egypt Biosimilars Porter's Five Forces
  • Egypt Biosimilars Industry Life Cycle
  • Historical Data and Forecast of Egypt Biosimilars Market Revenues & Volume By Product for the Period 2020 - 2030
  • Historical Data and Forecast of Egypt Biosimilars Market Revenues & Volume By Insulin for the Period 2020 - 2030
  • Historical Data and Forecast of Egypt Biosimilars Market Revenues & Volume By Follitropin for the Period 2020 - 2030
  • Historical Data and Forecast of Egypt Biosimilars Market Revenues & Volume By Calcitonin for the Period 2020 - 2030
  • Historical Data and Forecast of Egypt Biosimilars Market Revenues & Volume By Glucagon for the Period 2020 - 2030
  • Historical Data and Forecast of Egypt Biosimilars Market Revenues & Volume By Teriparatide for the Period 2020 - 2030
  • Historical Data and Forecast of Egypt Biosimilars Market Revenues & Volume By Others for the Period 2020 - 2030
  • Historical Data and Forecast of Egypt Biosimilars Market Revenues & Volume By Indication for the Period 2020 - 2030
  • Historical Data and Forecast of Egypt Biosimilars Market Revenues & Volume By Oncology for the Period 2020 - 2030
  • Historical Data and Forecast of Egypt Biosimilars Market Revenues & Volume By Offsite Treatment for the Period 2020 - 2030
  • Historical Data and Forecast of Egypt Biosimilars Market Revenues & Volume By Chronic Disorders for the Period 2020 - 2030
  • Historical Data and Forecast of Egypt Biosimilars Market Revenues & Volume By Blood Disorders for the Period 2020 - 2030
  • Historical Data and Forecast of Egypt Biosimilars Market Revenues & Volume By Infectious Diseases for the Period 2020 - 2030
  • Historical Data and Forecast of Egypt Biosimilars Market Revenues & Volume By Others for the Period 2020 - 2030
  • Historical Data and Forecast of Egypt Biosimilars Market Revenues & Volume By Manufacturing for the Period 2020 - 2030
  • Historical Data and Forecast of Egypt Biosimilars Market Revenues & Volume By Outsourced for the Period 2020 - 2030
  • Historical Data and Forecast of Egypt Biosimilars Market Revenues & Volume By In-house for the Period 2020 - 2030
  • Egypt Biosimilars Import Export Trade Statistics
  • Market Opportunity Assessment By Product
  • Market Opportunity Assessment By Indication
  • Market Opportunity Assessment By Manufacturing
  • Egypt Biosimilars Top Companies Market Share
  • Egypt Biosimilars Competitive Benchmarking By Technical and Operational Parameters
  • Egypt Biosimilars Company Profiles
  • Egypt Biosimilars Key Strategic Recommendations

Market Covered

The report offers a comprehensive study of the subsequent market segments:

By Product

  • Insulin
  • Follitropin
  • Calcitonin
  • Glucagon
  • Teriparatide
  • Others

By Indication

  • Oncology
  • Offsite Treatment
  • Chronic Disorders
  • Blood Disorders
  • Infectious Diseases
  • Others

By Manufacturing

  • Outsourced
  • In-House
Egypt Biosimilars Market (2024-2030): FAQs
The government initiatives to reduce healthcare costs, patent expirations of biologic drugs, and an increase in chronic diseases that require expensive biologics for treatment.
According to a report by Grand View Research, the Egyptian biosimilars market was valued at USD 5.0 million in 2019 and is expected to grow at a CAGR of 6.3% from 2024 to 2030.
The strict regulations for approval, lack of awareness among healthcare providers and patients, and concerns about quality and safety.
Yes, we provide customisation as per your requirements. To learn more, feel free to contact us on sales@6wresearch.com
1 Executive Summary
2 Introduction
2.1 Key Highlights of the Report
2.2 Report Description
2.3 Market Scope & Segmentation
2.4 Research Methodology
2.5 Assumptions
3 Egypt Biosimilars Market Overview
3.1 Egypt Country Macro Economic Indicators
3.2 Egypt Biosimilars Market Revenues & Volume, 2020 & 2030F
3.3 Egypt Biosimilars Market - Industry Life Cycle
3.4 Egypt Biosimilars Market - Porter's Five Forces
3.5 Egypt Biosimilars Market Revenues & Volume Share, By Form, 2020 & 2030F
3.6 Egypt Biosimilars Market Revenues & Volume Share, By Indication, 2020 & 2030F
3.7 Egypt Biosimilars Market Revenues & Volume Share, By Manufacturing, 2020 & 2030F
4 Egypt Biosimilars Market Dynamics
4.1 Impact Analysis
4.2 Market Drivers
4.3 Market Restraints
5 Egypt Biosimilars Market Trends
6 Egypt Biosimilars Market, By Types
6.1 Egypt Biosimilars Market, By Product
6.1.1 Overview and Analysis
6.1.2 Egypt Biosimilars Market Revenues & Volume, By Product, 2018 - 2027F
6.1.3 Egypt Biosimilars Market Revenues & Volume, By Insulin, 2018 - 2027F
6.1.4 Egypt Biosimilars Market Revenues & Volume, By Follitropin, 2018 - 2027F
6.1.5 Egypt Biosimilars Market Revenues & Volume, By Calcitonin, 2018 - 2027F
6.1.6 Egypt Biosimilars Market Revenues & Volume, By Glucagon, 2018 - 2027F
6.1.7 Egypt Biosimilars Market Revenues & Volume, By Teriparatide, 2018 - 2027F
6.1.8 Egypt Biosimilars Market Revenues & Volume, By Others, 2018 - 2027F
6.2 Egypt Biosimilars Market, By Indication
6.2.1 Overview and Analysis
6.2.2 Egypt Biosimilars Market Revenues & Volume, By Oncology, 2018 - 2027F
6.2.3 Egypt Biosimilars Market Revenues & Volume, By Offsite Treatment, 2018 - 2027F
6.2.4 Egypt Biosimilars Market Revenues & Volume, By Chronic Disorders, 2018 - 2027F
6.2.5 Egypt Biosimilars Market Revenues & Volume, By Blood Disorders, 2018 - 2027F
6.2.6 Egypt Biosimilars Market Revenues & Volume, By Infectious Diseases, 2018 - 2027F
6.2.7 Egypt Biosimilars Market Revenues & Volume, By Others, 2018 - 2027F
6.3 Egypt Biosimilars Market, By Manufacturing
6.3.1 Overview and Analysis
6.3.2 Egypt Biosimilars Market Revenues & Volume, By Outsourced, 2018 - 2027F
6.3.3 Egypt Biosimilars Market Revenues & Volume, By In-house, 2018 - 2027F
7 Egypt Biosimilars Market Import-Export Trade Statistics
7.1 Egypt Biosimilars Market Export to Major Countries
7.2 Egypt Biosimilars Market Imports from Major Countries
8 Egypt Biosimilars Market Key Performance Indicators
9 Egypt Biosimilars Market - Opportunity Assessment
9.1 Egypt Biosimilars Market Opportunity Assessment, By Product, 2020 & 2030F
9.2 Egypt Biosimilars Market Opportunity Assessment, By Indication, 2020 & 2030F
9.3 Egypt Biosimilars Market Opportunity Assessment, By Manufacturing, 2020 & 2030F
10 Egypt Biosimilars Market - Competitive Landscape
10.1 Egypt Biosimilars Market Revenue Share, By Companies, 2020
10.2 Egypt Biosimilars Market Competitive Benchmarking, By Operating and Technical Parameters
11 Company Profiles
12 Recommendations
13 Disclaimer
Pricing
  • Single User License
    $ 1,995
  • Department License
    $ 2,400
  • Site License
    $ 3,120
  • Global License
    $ 3,795
6Wresearch Support

Any Query

Call: +91-11-4302-4305
Email us: sales@6wresearch.com
Any Query? Click Here

Industry Events and Analyst Meet

Our Clients

Airtel
Canon
Contec
HoneyWell
Kriloskar
Pwc Logo
Samsung
Tata Teleservices

Whitepaper

Read All